Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asoprisnil safety extension in uterine fibroids
NCT00156195Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Sep 2003
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of asoprisnil in uterine leiomyoma, Menorrhagia and metrorrhagia (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Clinically meaningful improvement in bleeding without surgical intervention at 12 months. Started Sep 2003; status: completed.
02
Drugs
asoprisnil
03
Conditions
uterine leiomyomaMenorrhagiametrorrhagia
Beyond the preview
Go deeper on NCT00156195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00156195.